GENEART receives European Patent for Screening Process for Antiviral
- GENEART receives European Patent "Kernexportreportersystem"
("Nucleus Export Reporter System")
- System for screening of antiviral therapeutics is based on
customized synthetic genes
- Development emphasizes innovative potential of synthetic genes for
Regensburg, February 5, 2009 - GENEART AG, global leader in gene
synthesis and specialist in the field of Synthetic Biology, informs
of being awarded patent EP 1 356 111 "Kernexportreportersystem"
("Nucleus Export Reporter System") by the European patent office.
The patent describes a new screening system based on synthesized
virus-like reporter genes with which a new class of antiviral drug
candidates may be identified. Thus allowing to analyze by
high-throughput processes to which extent such drug candidates block
the export of viral messenger RNA from the cell nucleus and therefore
suppress virus propagation. Additionally, this process may be used
for identification of DNA motives positively affecting production
rates of cell factories and therefore production costs of proteins.
The patent covers Austria, Switzerland, Spain, Liechtenstein, France,
the United Kingdom, Luxemburg, the Netherlands, Sweden, Belgium,
Italy and Germany. The German patent of this family of patents had
been granted as early as 2008. An application for a comparable
protection for North America has been filed under the international
"With being granted the European patent, we did not only protect a
process with which new antiviral active agents can be identified
based on optimized genes, now we also have another proprietary
technology available, beside our gene optimizing software
GeneOptimizer®, to systematically improve production efficiency of
protein-based therapeutics and vaccines. This emphasizes again our
exceptional position as development partner for the pharmaceutical
industry as well as the innovative potential of synthetic genes for
research", explained Prof. Dr. Ralf Wagner, CEO of GENEART AG.
For further inquiries, please contact:
Phone: +49-(0)941-942 76-638
Fax: +49-(0)941-942 76-711
Better Orange IR & HV AG
This document may contain estimates, prognoses and opinions about
company plans and objectives, products or services, future results,
opinions about these results or opinions leading up to these results.
All these projections into the future are subject to risk,
uncertainty and unforeseeable change outside the control of the
GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.
About GENEART AG:
In 2000, GENEART entered the gene synthesis market and has since
become the global market leader. Today, the company is one of the
leading specialists in the Synthetic Biology field. Experts at
GENEART provide key technologies for the development and production
of new therapeutics and vaccines. Customers also take advantage of
GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct
bacteria, which produce complex biopolymers or break down polymers,
such as synthetics, petroleum components, etc. Our production and
service spectrum spans a wide range, from the production of synthetic
genes according to DIN EN ISO 9001:2000, to the creation of gene
libraries in the combinatorial biology, to the development and
production of DNA-based biologically active substances. GENEART AG in
Regensburg (Germany) and the subsidiaries GENEART Inc. in Toronto
(Canada) and GENEART Inc. in San Francisco (USA) employ more than 190
people. GENEART is listed on the German Stock Exchange.
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.
durchschnittliche Punktzahl: 0|